Teva subpoenaed by SEC investigating Latin American bribes
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has been subpoenaed by the US SEC and has begun an internal investigation into "certain business practices which may have FCPA implications", the company revealed in a note buried in its latest quarterly results filing with the US Securities and Exchange Commission.